Literature DB >> 11242189

Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of proteinase inhibitor-naive HIV-infected patients.

A Hänsel, H C Bucher, R Nüesch, M Battegay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11242189     DOI： 10.1097/00042560-200102010-00016

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  6 in total

1.  Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus.

Authors:  Parya Saberi; Dilrini K Ranatunga; Charles P Quesenberry; Michael J Silverberg
Journal:  Pharmacotherapy       Date:  2011-03       Impact factor: 4.705

2.  Evaluating competing adverse and beneficial outcomes using a mixture model.

Authors:  Bryan Lau; Stephen R Cole; Richard D Moore; Stephen J Gange
Journal:  Stat Med       Date:  2008-09-20       Impact factor: 2.373

3.  Short-term discontinuation of HAART regimens more common in vulnerable patient populations.

Authors:  Lindsay S Robison; Andrew O Westfall; Michael J Mugavero; Mirjam C Kempf; Stephen R Cole; Jeroan J Allison; James H Willig; James L Raper; C Mel Wilcox; Michael S Saag
Journal:  AIDS Res Hum Retroviruses       Date:  2008-11       Impact factor: 2.205

4.  Time to initial highly active antiretroviral therapy discontinuation and its predictors among HIV patients in Felege Hiwot comprehensive specialized hospital: a retrospective cohort study.

Authors:  Tewodros Getnet Amera; Kassawmar Angaw Bogale; Yibekal Manaye Tefera
Journal:  AIDS Res Ther       Date:  2021-12-04       Impact factor: 2.250

5.  Factors influencing adherence to antiretroviral treatment in Nepal: a mixed-methods study.

Authors:  Sharada P Wasti; Padam Simkhada; Julian Randall; Jennifer V Freeman; Edwin van Teijlingen
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

6.  Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age.

Authors:  Thiago Silva Torres; Sandra Wagner Cardoso; Luciane S Velasque; Valdilea G Veloso; Beatriz Grinsztejn
Journal:  Braz J Infect Dis       Date:  2013-09-09       Impact factor: 3.257
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.